You have 9 free searches left this month | for more free features.

PCI-32765

Showing 1 - 25 of 1,765

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Changchun, China
  • +5 more
Jan 27, 2023

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Breast Tumors, Malignant Tumor of Breast Trial in Dallas (Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg)

Recruiting
  • Breast Neoplasms
  • Malignant Neoplasm of Breast
  • Dallas, Texas
    10 sites incl TX, WA, VA, and NV
May 16, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia) Trial run by the NHLBI (PCI 32765)

Active, not recruiting
  • Leukemia
  • +3 more
  • PCI 32765
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 2, 2021

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Waldenstrom Macroglobulinemia Trial in Japan (Ibrutinib, Rituximab)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Chiba, Japan
  • +8 more
Jan 27, 2023

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

Chronic Lymphocytic Leukemia Trial in Columbus (biological, drug, other)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Daratumumab
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Stage I Chronic Lymphocytic Leukemia
  • +3 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 24, 2022

Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in United States (Ibrutinib,

Active, not recruiting
  • Metastatic Melanoma
  • +2 more
  • Los Angeles, California
  • +12 more
Jul 27, 2022

Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,

Withdrawn
  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • +8 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 2, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +4 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Completed
  • Loss of Chromosome 17p
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 4, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)

Completed
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
  • +1 more
Dec 5, 2022

Aplastic Anemia, Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor Trial in Columbus (Best Practice, Ibrutinib)

Active, not recruiting
  • Aplastic Anemia
  • +6 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 24, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Chronic Lymphocytic Leukemia, Loss of Chromosome 17p Trial (Ibrutinib, Venetoclax)

Withdrawn
  • Chronic Lymphocytic Leukemia
  • Loss of Chromosome 17p
  • (no location specified)
Oct 29, 2021

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)

Completed
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 10, 2021